Show simple item record

Desmoplakin as a Potential Candidate for Cerebrospinal Fluid Marker to Rule Out 14-3-3 False Positive Rates in Sporadic Creutzfeldt-Jakob Disease Differential Diagnosis

dc.contributor.authorGawinecka, Joanna
dc.contributor.authorCiesielczyk, Barbara
dc.contributor.authorSanchez-Juan, Pascual
dc.contributor.authorSchmitz, Matthias
dc.contributor.authorHeinemann, Uta
dc.contributor.authorZerr, Inga
dc.date.accessioned2013-06-04T11:19:26Z
dc.date.available2013-06-04T11:19:26Z
dc.date.issued2012
dc.relation.ISSN1660-2862
dc.identifier.urihttp://resolver.sub.uni-goettingen.de/purl?gs-1/9091
dc.description.abstractBackground: The detection of a 14-3-3 elevated level in cerebrospinal fluid (CSF) is a part of the diagnostic criteria for probable sporadic Creutzfeldt-Jakob disease (sCJD), as defined by the WHO. However, some pathological conditions associated with acute neuronal damage may result in a positive 14-3-3 test and thereby reduce test specificity in sCJD. Objective: Desmoplakin has been previously identified as up-regulated CSF protein in sCJD and these studies aimed to investigate its diagnostic utility and compare it with two known CSF markers, 14-3-3 and tau. Methods and Results: We tested CSF levels of 14-3-3, tau and desmoplakin in 58 sCJD patients and 81 control patients including 45 cases with an elevated 14-3-3 level due to other disease than sCJD. We detected an elevated CSF level of desmoplakin in 78% of the sCJD patients, while 14-3-3 (88%) and tau (91%) showed a higher positive rate. However, the false positive rate of newly tested desmoplakin was significantly lower in comparison to 14-3-3 and tau, and it accounted for only 11% versus 56% and 35%, respectively. Further reduction of false positive rates was achieved by combination of elevated tau level with a positive desmoplakin test. Moreover, in the non-sCJD group, desmoplakin level did not correlate with the level of both above-mentioned CSF markers, whereas a clear correlation was observed in the sCJD group. Conclusion: Desmoplakin showed a low positive rate accompanied by a very low false positive rate. Thus, we conclude that desmoplakin is a promising candidate for supportive CSF marker to rule out 14-3-3 false positive cases in sCJD differential diagnosis.
dc.language.isoeng
dc.relationinfo:eu-repo/grantAgreement/EC/FP7/222887/EU//PRIORITY
dc.rightsopenAccess
dc.subjectCSF marker; Creutzfeldt-Jakob disease; Desmoplakin; 14-3-3; Tau
dc.titleDesmoplakin as a Potential Candidate for Cerebrospinal Fluid Marker to Rule Out 14-3-3 False Positive Rates in Sporadic Creutzfeldt-Jakob Disease Differential Diagnosis
dc.typejournalArticle
dc.identifier.doi10.1159/000334499
dc.type.versionpublishedVersion
dc.identifier.fs585257
dc.relation.pISSN1660-2854
dc.bibliographicCitation.volume9
dc.bibliographicCitation.issue3
dc.bibliographicCitation.firstPage139
dc.bibliographicCitation.lastPage144
dc.type.subtypejournalArticle
dc.identifier.pmid22213780
dc.notesThis publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.
dc.relation.euprojectPRIORITY
dc.description.statuspeerReviewed
dc.bibliographicCitation.journalNeurodegenerative Diseases


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record